Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LEGN 
Legend Biotech Corp (LEGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: LEGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $75.06
1 Year Target Price $75.06
| 11 | Strong Buy |
| 10 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.65% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.98B USD | Price to earnings Ratio - | 1Y Target Price 75.06 |
Price to earnings Ratio - | 1Y Target Price 75.06 | ||
Volume (30-day avg) 22 | Beta 0.23 | 52 Weeks Range 27.34 - 47.79 | Updated Date 11/1/2025 |
52 Weeks Range 27.34 - 47.79 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -40.83% | Operating Margin (TTM) -8.58% |
Management Effectiveness
Return on Assets (TTM) -7.81% | Return on Equity (TTM) -29.65% |
Valuation
Trailing PE - | Forward PE 19.46 | Enterprise Value 5380145048 | Price to Sales(TTM) 7.5 |
Enterprise Value 5380145048 | Price to Sales(TTM) 7.5 | ||
Enterprise Value to Revenue 6.75 | Enterprise Value to EBITDA -15.34 | Shares Outstanding 184570705 | Shares Floating 162765522 |
Shares Outstanding 184570705 | Shares Floating 162765522 | ||
Percent Insiders 1.3 | Percent Institutions 47.39 |
Upturn AI SWOT
Legend Biotech Corp
Company Overview
History and Background
Legend Biotech Corp was founded in 2014 and focuses on the discovery and development of novel cell therapies for oncology and other indications. It is a global biotechnology company headquartered in Somerset, New Jersey.
Core Business Areas
- Cell Therapy Development: Focuses on developing novel cell therapies, primarily CAR-T therapies, for hematological malignancies and solid tumors.
- Manufacturing: Establishes and maintains manufacturing capabilities to produce cell therapies for clinical trials and commercial supply.
- Research and Development: Conducts research and development activities to discover and advance new therapeutic candidates.
Leadership and Structure
The leadership team consists of key executives overseeing R&D, operations, and commercialization. The organizational structure includes research, clinical development, manufacturing, and commercial divisions.
Top Products and Market Share
Key Offerings
- Carvykti (ciltacabtagene autoleucel): Carvykti is a BCMA-directed CAR-T cell therapy approved for the treatment of relapsed or refractory multiple myeloma in adults. The market share information is still evolving, but it is a significant competitor to other CAR-T therapies. Competitors include Abecma (Bristol Myers Squibb/bluebird bio) and potentially other emerging therapies.
Market Dynamics
Industry Overview
The industry is in high growth with continuous innovation of novel drug therapies such as CAR-T and other advanced biotechnologies. There is a great deal of competition to get approval to target areas with high unmet need.
Positioning
Legend Biotech is positioned as a leader in the CAR-T therapy field, particularly for multiple myeloma. Its competitive advantages include the clinical efficacy of Carvykti and its established manufacturing capabilities. They partnered with Janssen to develop and commercialize Carvykti.
Total Addressable Market (TAM)
The CAR-T therapy market is expected to reach billions of dollars in the coming years. Legend Biotech, with Carvykti, is positioned to capture a significant share of this growing market.
Upturn SWOT Analysis
Strengths
- Innovative CAR-T platform
- Strong clinical trial results for Carvykti
- Strategic partnership with Janssen
- Established manufacturing capabilities
- Strong financial position
Weaknesses
- High manufacturing costs associated with CAR-T therapies
- Competition from other CAR-T therapies
- Potential for adverse events associated with CAR-T therapies
- Limited commercial experience as a relatively new company
Opportunities
- Expansion of Carvykti's label to earlier lines of therapy
- Development of new CAR-T therapies for other cancers
- Strategic collaborations to expand pipeline
- Global expansion of commercial operations
Threats
- Regulatory hurdles and approval delays
- Pricing pressures and reimbursement challenges
- Emergence of new and competitive therapies
- Potential for manufacturing disruptions
Competitors and Market Share
Key Competitors
- BMY
Competitive Landscape
Legend Biotech's Carvykti competes with other BCMA-directed therapies, including Abecma from Bristol Myers Squibb. Legend's advantage lies in Carvykti's efficacy, but competition remains intense.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced rapid growth in recent years, driven by clinical progress and the commercial launch of Carvykti.
Future Projections: Analysts project continued revenue growth for Legend Biotech, driven by increased adoption of Carvykti and potential expansion into new indications.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, conducting clinical trials for new indications, and building out commercial infrastructure.
Summary
Legend Biotech is a promising biotechnology company focused on CAR-T cell therapies, particularly for multiple myeloma. The successful development and commercialization of Carvykti, in partnership with Janssen, has driven significant revenue growth. While facing competition and manufacturing challenges, Legend Biotech is positioned to capitalize on the growing CAR-T therapy market. Continued pipeline expansion and strategic initiatives will be critical for long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Legend Biotech Corp
Exchange NASDAQ | Headquaters Somerset, NJ, United States | ||
IPO Launch date 2020-06-05 | CEO & Director Dr. Ying Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.legendbiotech.com |
Full time employees 2800 | Website https://www.legendbiotech.com | ||
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.